Dr. Burris on Updated MONALEESA-2 Trial Results for HR+ Breast Cancer

Updated Results of the MONALEESA-2 Trial in HR+/HER2- Breast CancerПодробнее

MONALEESA-2: ribociclib + letrozole in pts with de novo metastatic disease and late recurrenceПодробнее

MONALEESA-2: improved OS seen in HR+ advanced breast cancer treated with ribociclib + letrozoleПодробнее

Dr. Varella on the Results of MONALEESA-7 in HR+/HER2- Breast CancerПодробнее

Dr. Hortobagyi on MONALEESA-2 Trial Results in Breast CancerПодробнее

Dr. Gabriel Hortobagyi on the Impact of MONALEESA-2 Trial in HR+ Breast CancerПодробнее

Results of the MONALEESA-2 Study in Advanced Breast CancerПодробнее

Dr. Slamon on OS Results of the MONALEESA-3 Trial in HR+/HER2- Breast CancerПодробнее

Dr. Slamon the Phase III Results of MONALEESA-3 Trial in HR+/HER2- Breast CancerПодробнее

Gabriel Hortobagyi:Подробнее

MONALEESA-3 OS results: fulvestrant/ribociclib in postmenopausal HR+/HER2- advanced breast cancerПодробнее

MONALEESA-7: Results from phase III trial looking at ribociclib as an addition to endocrine ther...Подробнее

ESMO 2016: Press brief on the MONALEESA-2 clinical trial on breast cancerПодробнее

QOL in MONALEESA-2, 3, and 7Подробнее

Early RIBECCA results: ribociclib with letrozole for metastatic breast cancerПодробнее

Overall survival results from MONALEESA-3 study on ribociclib plus fulvestrant in advanced breas...Подробнее

GS2-01: "Overall survival subgroup analysis by metastatic site from the phase3 MONALEESA-2..."Подробнее

Safety and efficacy of ribociclib and letrozole in advanced breast cancer – the MONALEESA-2 trialПодробнее

Overall survival results from MONALEESA-2: Endocrine therapy and ribociclib in HR positive and H...Подробнее